DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS

Kondo M, Suzuki T, Kawano Y, Kojima S, Miyashiro M, Matsumoto A, Kania G, Blyszczuk P, Ross R, Mulipa P, Del Galdo F, Zhang Y, Distler J (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 488-488

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2022-eular.29

Authors with CRIS profile

Jörg Distler Professur für Molekulare Mechanismen der Organfibrose

Involved external institutions

Mitsubishi Tanabe Pharma Corporation JP Japan (JP) University of Leeds GB United Kingdom (GB) University of Zurich / Universität Zürich (UZH) CH Switzerland (CH)

How to cite

APA:

Kondo, M., Suzuki, T., Kawano, Y., Kojima, S., Miyashiro, M., Matsumoto, A.,... Distler, J. (2022). DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases, 488-488. https://doi.org/10.1136/annrheumdis-2022-eular.29

MLA:

Kondo, M., et al. "DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS." Annals of the Rheumatic Diseases (2022): 488-488.

BibTeX: Download